Res Consortium, Andover, UK.
Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
Int J Clin Pract. 2021 Sep;75(9):e14228. doi: 10.1111/ijcp.14228. Epub 2021 Jul 6.
The approach to thyroid hormone replacement varies across centres, but the extent and determinants of variation is unclear. We evaluated geographical variation in levothyroxine (LT4) and liothyronine (LT3) prescribing across General Practices in England and analysed the relationship of prescribing patterns to clinical and socioeconomic factors.
Data was downloaded from the NHS monthly General Practice Prescribing Data in England for the period 2011-2020.
The study covered a population of 19.4 million women over 30 years of age, attending 6,660 GP practices and being provided with 33.7 million prescriptions of LT4 and LT3 at a total cost of £90million/year. Overall, 0.5% of levothyroxine treated patients continue to receive liothyronine. All Clinical Commission Groups (CCGs) in England continue to have at least one liothyronine prescribing practice and 48.5% of English general practices prescribed liothyronine in 2019-2020. Factors strongly influencing more levothyroxine prescribing (model accounted for 62% of variance) were the CCG to which the practice belonged and the proportion of people with diabetes registered on the practice list plus antidepressant prescribing, with socioeconomic disadvantage associated with less levothyroxine prescribing. Whereas factors that were associated with increased levels of liothyronine prescribing (model accounted for 17% of variance), were antidepressant prescribing and % of type 2 diabetes mellitus individuals achieving HbA1c control of 58 mmol/mol or less. Factors that were associated with reduced levels of liothyronine prescribing included smoking and higher obesity rates.
In spite of strenuous attempts to limit prescribing of liothyronine in general practice a significant number of patients continue to receive this therapy, although there is significant geographical variation in the prescribing of this as for levothyroxine, with specific general practice and CCG-related factors influencing prescribing of both levothyroxine and liothyronine across England.
甲状腺激素替代治疗的方法因中心而异,但变化的程度和决定因素尚不清楚。我们评估了英格兰普通诊所中左甲状腺素(LT4)和三碘甲状腺原氨酸(LT3)的开具情况,并分析了开具模式与临床和社会经济因素的关系。
从 2011 年至 2020 年期间,从英国国家医疗服务体系每月的普通诊所处方数据中下载数据。
该研究涵盖了 1940 万 30 岁以上的女性人群,她们在 6660 家全科医生诊所就诊,并接受了 3370 万次 LT4 和 LT3 处方,总费用为每年 9000 万英镑。总体而言,0.5%的左甲状腺素治疗患者仍继续接受三碘甲状腺原氨酸治疗。英格兰所有临床委托组(CCG)都至少有一个开具三碘甲状腺原氨酸的实践,48.5%的英格兰普通实践在 2019-2020 年开具三碘甲状腺原氨酸。强烈影响更多左甲状腺素处方的因素(模型解释了 62%的方差)是实践所属的 CCG 以及实践登记册上患有糖尿病和抗抑郁药处方的人数比例,社会经济劣势与更少的左甲状腺素处方相关。而与增加三碘甲状腺原氨酸处方相关的因素(模型解释了 17%的方差)是抗抑郁药处方和 2 型糖尿病患者的 HbA1c 控制在 58mmol/mol 或更低的比例。与减少三碘甲状腺原氨酸处方相关的因素包括吸烟和更高的肥胖率。
尽管在普通实践中极力限制三碘甲状腺原氨酸的开具,但仍有相当数量的患者继续接受这种治疗,尽管与左甲状腺素一样,三碘甲状腺原氨酸的开具存在显著的地域差异,具体的普通实践和 CCG 相关因素影响着英格兰各地左甲状腺素和三碘甲状腺原氨酸的开具。